EGFR and non-small cell lung carcinoma: Although not explored in detail here, the observed enhanced sensitivity to gefitinib upon USP54 knockdown suggests that targeting USP54 alongside EGFR may offer a promising dual-inhibition strategy to overcome NSCLC resistance.